Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the ...

Tom Nolan reviews this week’s research Critics argue that limited dosing options for polypills mean patients get suboptimal ...

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE)-- Beam Therapeutics Inc. (Nasdaq: BEAM), ...

Leading cardiovascular societies have developed the second universal definition of heart failure that updates how it is classified and identified, hoping to improve diagnosis and management.

Reduced vascular compressibility between inspiration and expiration was associated with increased asthma severity and inflammation.

The dean of FAU’s medical school writes that a new pledge to include nutrition education being asked of schools by the U.S.

Yu Sleep launches nano-enhanced liquid sleep formula amid CDC data showing one in three U.S. adults are sleep-deprived ...

Experts hope the FAI score can become the next big tool in personalized risk assessment, though costs remain unknown.

BackgroundThalassemia remains one of the most prevalent inherited hematologic disorders worldwide and continues to represent ...

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.

A glucagon and GLP-1 receptor dual agonist showed promise for reducing liver fat in a phase II study of patients with metabolic dysfunction-associated steatotic liver disease and steatohepatitis. ( ...

Autoantibodies are central to the diagnosis, classification, and stratification of many autoimmune diseases, particularly ...